Dissecting the clinicopathologic,genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer |
| |
| Affiliation: | 1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA;2. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA;3. Harvard School of Public Health, Boston, USA;4. Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK;5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA;6. Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, USA;7. Knowledge Systems Group, Dana-Farber Cancer Institute, Boston, USA;8. ImmunoProfile, Brigham & Women’s Hospital and Dana-Farber Cancer Institute, Boston, USA;9. Department of Pathology, Brigham and Women’s Hospital, Boston, USA;10. Department of Radiology, Brigham and Women’s Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, USA;11. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA;12. Molecular Biotechnology and Health Science, University of Turin, Turin, Italy |
| |
| Abstract: | |
| |
| Keywords: | KRAS G12D PD-(L)1 blockade NSCLC |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
